HitGen Inc. entered into a research collaboration agreement with DAEWOONG PHARMACEUTICAL Co. Ltd. HitGen will apply its DNA-encoded library (DEL) technology platform centered around the design, synthesis and screening of thousands of DELs that collectively comprise over 1.2 trillion small, drug-like molecules to discover compounds that bind to certain targets that Daewoong needs to discover for new drug development.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
11.35 CNY | -0.09% | -4.22% | -24.28% |
04-24 | HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
02-23 | HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-24.28% | 624M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- 688222 Stock
- News HitGen Inc.
- DAEWOONG PHARMACEUTICAL Co., Ltd and HitGen Inc. Announces Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery